From: www.ecancer.tv on Tue, Mar 01 2011 7:32 PM

Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line treatmen...

From: www.ecancer.tv on Tue, Mar 01 2011 7:32 PM

The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and re...

From: www.ecancer.tv on Tue, Mar 01 2011 7:32 PM

Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.

From: www.ecancer.tv on Tue, Mar 01 2011 7:32 PM

Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib (V...

From: www.ecancer.tv on Wed, Feb 23 2011 6:34 PM

Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular non-H...

From: www.ecancer.tv on Mon, Feb 21 2011 4:32 PM

Prof Valeria Santini talks about the results of her research on the use of comorbidity indexes to determine prognosis for elderly myelodysplastic syndrome patients treated with azacitidine. This trial found that elderly patients with comorbidities can be treated successfully with azacitidine with...

From: www.ecancer.tv on Mon, Feb 21 2011 4:26 PM

The groundbreaking introduction of the tyrosine kinase inhibitor (TKI) imatinib as a treatment for chronic myeloid leukaemia (CML) has been followed by the introduction of further second and third generation TKIs. The panel discuss how TKIs act, the effect they have on patients in terms of their...

From: www.ecancer.tv on Mon, Feb 21 2011 4:09 PM

Prof George Canellos talks about the key research that has emerged from the 2010 ASH meeting in Florida. One trial of note compared the Stanford V treatment regimen with ABVD for patients with advanced Hodgkin’s lymphoma and revealed that Stanford V was not superior to ABVD. Prof Canellos explain...

From: www.ecancer.tv on Fri, Feb 18 2011 5:36 PM

Prof Timothy Hughes speaks to ecancer.tv about the ENESTnd trial which is evaluating the efficacy and safety of the second generation tyrosine kinase inhibitor nilotinib in newly diagnosed chronic myeloid leukaemia (CML) patients. This study compared standard imatinib treatment with nilotinib 300...

From: www.ecancer.tv on Fri, Feb 18 2011 5:36 PM

Dr Reinhard Stauder speaks about his aims for the upcoming ecancer meeting on haematological cancers in elderly patients, Rome, 18-20th March 2011. This meeting will address the difficulties faced when treating older cancer patients, provide recommendations for best practice and work to define t...

From: www.ecancer.tv on Fri, Feb 18 2011 1:00 PM

Dr Michael Keating discusses his pick of the research presented at ASH 2010. This includes trials looking at new tyrosine kinase inhibitors that target LIM-kinase, Syk, PI 3-kinase delta or BTK. Due to the low levels of toxicity, these TKIs are potentially ideal front line therapies for older ca...

From: www.ecancer.tv on Fri, Feb 18 2011 1:00 PM

Prof Kanti Rai discusses advances that have been made in the treatment of chronic lymphocytic leukaemia (CLL). Key research presented at this years ASH congress has demonstrated that previously untreated patients who do not want or are unsuitable for chemotherapy can be successfully treated with ...

From: www.ecancer.tv on Fri, Feb 18 2011 12:59 PM

Prof Pieter Sonneveld speaks about a trial evaluating the efficacy of bortezomib during induction and maintenance therapy on progression-free survival in patients with multiple myeloma. A higher level of complete response was seen when bortezomib was used in place of vincristine during induction ...

From: www.ecancer.tv on Fri, Feb 18 2011 12:59 PM

Prof Wyndham Wilson provides a comprehensive summary of the key lymphoma related research presented at the 2010 ASH congress in Florida. The first study discussed demonstrates that treating asymptomatic advanced stage follicular lymphoma patients with Rituxan (rituximab) rather than using the sta...

From: www.ecancer.tv on Fri, Feb 18 2011 12:58 PM

Dr William Matsui speaks about plasma cell biology and how this affects cancer growth. In multiple myeloma, malignant plasma cells make up the vast majority of tumour cells and are thought to be responsible for tumour growth. Dr Matsui speaks about the aims and challenges facing his work evaluat...

From: www.ecancer.tv on Fri, Feb 18 2011 10:57 AM

Jan Geissler speaks about some of the key research into chronic myeloid leukaemia (CML) that has been presented at ASH 2010. This includes papers on the second generation tyrosine kinase inhibitors dasatinib, erlotinib and ponatinib, a poster presentation indicating that imatinib treatment does ...

From: www.ecancer.tv on Fri, Feb 18 2011 10:57 AM

Jan Geissler speaks about the upcoming ecancer meeting on haematological cancers in the elderly which will be held in Rome, 18-20th March 2011. This meeting will tackle issues such as the inclusion of elderly patients in clinical trials, the effects of comorbidities and the type of therapies tha...

From: www.ecancer.tv on Fri, Feb 18 2011 10:57 AM

Dr Jerald Radich speaks about the treatment options that are available for chronic myeloid leukaemia (CML). Tyrosine kinase inhibitors such as imatinib dasatinib and erlotinib have allowed to clinicians to effectively treat CML without the need for transplantation. However there is still a portio...

From: www.ecancer.tv on Fri, Feb 18 2011 10:57 AM

Prof Stephen Baylin speaks to ecancertv about epigenetics. He explains what epigenetics is, how it is being used to treat cancer and how it may potentially be used in the future. Prof Baylin discusses epigenetic mapping and talks about clinical trials that are being established in the Unites Sta...

From: www.ecancer.tv on Fri, Feb 18 2011 8:47 AM

Prof Giuseppe Saglio speaks about the DASISION trial which compares dasatinib with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP). Cardiovascular disease is an important comorbidity in some patients with CML-CP and this study as...